Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%

Trial Profile

Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Temozolomide
  • Indications Gastrointestinal cancer; Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Jun 2015 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 26 Jun 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top